Transfersomes Mediated Transepidermal Delivery Improves
the Regio-Specificity and Biological Activity of Corticosteroids in vivo
Gregor Cevc*, G. Blume,+ and A. Schätzlein*+
+IDEA, Innovative dermale Applikationen GmbH, Frankfurter
Ring 193a,
D-80807 München, Deutschland, EU
*Medizinische Biophysik, Klinikum r.d.I., Technische Universität München,
Ismaningerstr. 22, D-81675 München, Deutschland, EU
Journal of Controlled Release 45: 211-226 (1996).
Innovative, carrier-based suspensions of several commonly
used corticosteroids are introduced. These formulations contain the recently
developed agent carriers, Transfersomes, which are sufficiently deformable
to penetrate into or across the intact skin barrier. The resulting drug
delivery can be varied systematically: depending on the precise application
conditions and carrier design, between 100 % and < 5 % of applied drug
is deposited in the outermost skin region. Low area dose favours the drug
retention in the skin and keeps the relative area under the curve for
the blood pool below a few per cent, at most, of that resulting from the
corresponding drug injection; transfersomes hence improve the specificity
of topical drug delivery and the overall drug safety. Increasing the total
applied drug dose, as well as the dose per area, promotes the systemic
drug availability. After an epicutaneous application of sufficient drug
amount, therapeutically meaningful agent concentration is reached in the
blood. This normally happens after the lag time of approximately 4 h to
6 h. When hydrocortisone, dexamethasone, or triamcinolone-acetonide are
administered epicutaneously in transfersomes, for example, at the dose
of 1.5 mg/kg, 1.5 mg/kg, and 1 mg/kg, the respective concentrations of
these drugs in the blood at t=8 h are approximately 0.4 µg/mL,
near 0.75 µg/mL and 0.007 µg/mL. These results are
comparable to those of a subcutaneous
injection of (3 ... 10 x) lower amounts of the same drug. Concentration
of the epicutaneously administered corticosteroids in the blood is always
lower than in the skin, however, where 28 µg/g, 156 µg/g, and 10 µg/g
are found for the above mentioned drug doses at t=8 h, respectively. Transfersome-based
corticosteroids are biologically active at doses several times lower than
that currently used in the dermatic formulations for the treatment of
skin diseases. The biological anti-edema activity of transfersomal corticosteroid
formulations hence exceeds that of the corresponding commercial products,
probably owing to the superior drug targeting potential in the organ.
<---- |
Startseite |
Über uns |
Corporate Factsheet |
Wissenschaft |
Publikationen |
Einsatzmöglichkeiten |
Finanzierung |
Pressemitteilungen |
Letzter Newsletter |
Pressespiegel |
Konferenzen |
Karriere |
Kontakt |
Wissenschaftliche FAQ |
Glossar |
Seitenübersicht |
Suchen |